BioSpace News Archive

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today announced the creation of the Global HIV and COVID-19 Emergency Response Fund. The £3 million fund will make available critical financial resources for research projects to study the medical and scientific impact COVID-19 is having on people living with HIV and community-based grants to help addr

Proscia®, a leading provider of AI-enabled digital pathology solutions, has made available the Concentriq Dx® digital pathology software for use in reviewing and reporting of digital pathology slides in the United States.

Transparency Market Research PVT. LTD (TMR) has published a new report titled, “DNA Test Kits Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019–2027”.

Public health issues are expanding with every passing year and donning a prominent place in the list are visual disorders and blindness, paving the way for heated discussions on the way forward.

As per a recent Transparency Market Research PVT. LTD report on global opioid tolerance treatment market states the market is anticipated to witness a substantial growth during 2019 to 2027.

Performacide® included on EPA’s list of products qualified for use against virus that causes COVID-19

Tarveda Therapeutics, Inc. , a clinical stage biopharmaceutical company developing a new class of potent and selective precision oncology medicines, which it refers to as Pentarin® miniature drug conjugate

EOS imaging (Paris:EOSI) (Euronext, FR0011191766 - EOSI - PEA-PME eligible), a leader in 2D/3D orthopedic medical imaging and software solutions for 3D anatomical modeling and surgical planning, today announces its consolidated annual results for the year to December 31, 2019 and its revenues for the first quarter of 2020, as approved by the Board of Directors on April 27, 2020. A year 2019 marke

April 27, 2020 19:00 UTC Personal Genome Diagnostics Receives FDA Clearance for PGDx elio™ tissue complete , the First Comprehensive Genomic Profiling Diagnostic Kit for Oncology PGDx elio™ tissue complete is the industry’s first and only clinical next-generation sequencing (NGS) diagnostic kit for comprehensive tumor profiling that is FDA-cleared for use in labs across the country PGDx elio™ tissue complete increases patient access to precision-based comprehensive genomic

Corcept Therapeutics Incorporated announced it will report first quarter financial results and provide a corporate update on May 4, 2020.